Immix Biopharma (NASDAQ: IMMX)

Currency in USD

Last close As at 09/06/2023


0.06 (3.05%)

Market capitalisation


Immix Biopharma’s lead asset, IMX-110, is being investigated in a Phase Ib/IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumors in combination with the ICI tislelizumab. Immix also has a pre-clinical pipeline based on the TSTx technology.

With IMX-110 Immix is targeting the soft tissue sarcoma market, a rare cancer with c 13,000–16,000 new cases reported in the United States each year and limited safe and effective treatment options. IMX-110’s combination study may further expand the drug’s offering into new indications.

Scientist using protective robber gloves for handling substances and experiments



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Dr Ilya Rachman


  • Gabriel Morris


Balance Sheet

Forecast net debt (US$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (14.3) 2.0 (9.0)
Relative (17.5) (5.2) (12.7)
52 week high/low US$3.1/US$0.8


Immix Biopharma is a clinical-stage biopharmaceutical company focused on the development of its SMARxT tissue-specific platform producing tissue-specific therapeutics (TSTx). Its lead clinical asset, IMX-110, is being investigated for the treatment of soft tissue sarcoma, where interim results from its Phase Ib trial have, so far, demonstrated positive safety and efficacy profiles. Management intends to initiate a Phase IIa of the study in first-line soft tissue sarcoma in 2023. In Q422 Immix reported dosing of the first two patients in a Phase Ib/IIa study, investigating the use of IMX-110 in combination with tislelizumab in the treatment of solid tumors. We expect rolling data readouts across both studies throughout 2023. Immix Biopharma’s CAR-T therapy NXC-201 continues to demonstrate high response rates in multiple myeloma and AL amyloidosis from the Phase I/II NEXICART-1 study.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2021A 0.0 (1.4) (1.3) (35.91) N/A N/A
2022A 0.0 (8.2) (7.7) (55.49) N/A N/A
2023E 0.0 (10.9) (10.5) (71.81) N/A N/A
2024E 0.0 (14.4) (14.0) (93.33) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free